Emma Hobson
Chapel Allerton Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Emma Hobson.
European Journal of Human Genetics | 2012
Siddharth Banka; Ratna Veeramachaneni; William Reardon; Emma Howard; Sancha Bunstone; Nicola Ragge; Michael J. Parker; Yanick J. Crow; Bronwyn Kerr; Helen Kingston; Kay Metcalfe; Kate Chandler; Alex Magee; Fiona Stewart; Vivienne McConnell; Deirdre E. Donnelly; Siren Berland; Gunnar Houge; Jenny Morton; Christine Oley; Nicole Revencu; Soo Mi Park; Sally Davies; Andrew E. Fry; Sally Ann Lynch; Harinder Gill; Susann Schweiger; Wayne W K Lam; John Tolmie; Shehla Mohammed
MLL2 mutations are detected in 55 to 80% of patients with Kabuki syndrome (KS). In 20 to 45% patients with KS, the genetic basis remains unknown, suggesting possible genetic heterogeneity. Here, we present the largest yet reported cohort of 116 patients with KS. We identified MLL2 variants in 74 patients, of which 47 are novel and a majority are truncating. We show that pathogenic missense mutations were commonly located in exon 48. We undertook a systematic facial KS morphology study of patients with KS at our regional dysmorphology meeting. Our data suggest that nearly all patients with typical KS facial features have pathogenic MLL2 mutations, although KS can be phenotypically variable. Furthermore, we show that MLL2 mutation-positive KS patients are more likely to have feeding problems, kidney anomalies, early breast bud development, joint dislocations and palatal malformations in comparison with MLL2 mutation-negative patients. Our work expands the mutation spectrum of MLL2 that may help in better understanding of this molecule, which is important in gene expression, epigenetic control of active chromatin states, embryonic development and cancer. Our analyses of the phenotype indicates that MLL2 mutation-positive and -negative patients differ systematically, and genetic heterogeneity of KS is not as extensive as previously suggested. Moreover, phenotypic variability of KS suggests that MLL2 testing should be considered even in atypical patients.
European Journal of Human Genetics | 2008
John C.K. Barber; Viv Maloney; Shuwen Huang; David J. Bunyan; Lara Cresswell; Esther Kinning; Anna Benson; Tim Cheetham; Jonathan Wyllie; Sally Ann Lynch; Simon Zwolinski; Laura Prescott; Yanick J. Crow; Rob Morgan; Emma Hobson
The 8p23.1 deletion syndrome is established but not an equivalent duplication syndrome. Here, we report five patients; a de novo prenatal case and two families in which 8p23.1 duplications have been directly transmitted from mothers to children. Dual-colour fluorescent in situ hybridisation, multiplex ligation-dependent probe amplification analysis and customised oligonucleotide array comparative genomic hybridisation (oaCGH) indicated an ∼3.75 Mb duplication of most of band 8p23.1 between the olfactory receptor/defensin repeats (ORDRs) in all cases. However, oaCGH revealed an additional duplication of 500 kb adjacent to the proximal ORDR in Family 1 and an additional deletion of 3.14 Mb within the Nablus Mask-Like Facial Syndrome region of 8q22.1 in Family 2. Copy number variation at introns 4–5 of the GATA4 gene was also identified. This 8p23.1 duplication syndrome is associated with a characteristic facial phenotype including a prominent forehead and arched eyebrows. Adrenal insufficiency, Tetralogy of Fallot, partial 2/3 syndactyly of the toes and cleft palate in some individuals may be explained by ascertainment bias, incomplete penetrance and/or the presence of the microdeletion in Family 2. The duplication is compatible with normal early childhood development but, although our adult cases live independent lives with varying degrees of support, learning difficulties have been experienced by some family members. We conclude that the 8p23.1 duplication syndrome is a genomic condition with an emerging but variable phenotype that may be under-diagnosed. Our results demonstrate that direct transmission does not distinguish genuine duplications from euchromatic variants and illustrate the power of array CGH to reveal unexpected additional imbalances in affected patients.
European Journal of Human Genetics | 2009
Jill Clayton-Smith; Sarah Walters; Emma Hobson; Emma Burkitt-Wright; Rupert Smith; Annick Toutain; Jeanne Amiel; Stanislas Lyonnet; Sahar Mansour; David Fitzpatrick; Roberto Ciccone; Ivana Ricca; Orsetta Zuffardi; Dian Donnai
Xq28 duplications encompassing MECP2 have been described in male patients with a severe neurodevelopmental disorder associated with hypotonia and spasticity, severe learning disability and recurrent pneumonia. We identified an Xq28 duplication in three families where several male patients had presented with intestinal pseudo-obstruction or bladder distension. The affected boys had similar dysmorphic facial appearances. Subsequently, we ascertained seven further families where the proband presented with similar features. We demonstrated duplications of the Xq28 region in five of these additional families. In addition to MECP2, these duplications encompassed several other genes already known to be associated with diseases including SLC6A8, L1CAM and Filamin A (FLNA). The two remaining families were shown to have intragenic duplications of FLNA only. We discuss which elements of the Xq28 duplication phenotype may be associated with the various genes in the duplication. We propose that duplication of FLNA may contribute to the bowel and bladder phenotype seen in these seven families.
PLOS Genetics | 2012
Tomoo Ogi; Sarah R. Walker; Tom Stiff; Emma Hobson; Siripan Limsirichaikul; Gillian Carpenter; Katrina Prescott; Mohnish Suri; Philip J. Byrd; Michiko Matsuse; Norisato Mitsutake; Yuka Nakazawa; Pradeep Vasudevan; Margaret Barrow; Grant S. Stewart; A. Malcolm R. Taylor; Mark O'Driscoll; Penny A. Jeggo
A homozygous mutational change in the Ataxia-Telangiectasia and RAD3 related (ATR) gene was previously reported in two related families displaying Seckel Syndrome (SS). Here, we provide the first identification of a Seckel Syndrome patient with mutations in ATRIP, the gene encoding ATR–Interacting Protein (ATRIP), the partner protein of ATR required for ATR stability and recruitment to the site of DNA damage. The patient has compound heterozygous mutations in ATRIP resulting in reduced ATRIP and ATR expression. A nonsense mutational change in one ATRIP allele results in a C-terminal truncated protein, which impairs ATR–ATRIP interaction; the other allele is abnormally spliced. We additionally describe two further unrelated patients native to the UK with the same novel, heterozygous mutations in ATR, which cause dramatically reduced ATR expression. All patient-derived cells showed defective DNA damage responses that can be attributed to impaired ATR–ATRIP function. Seckel Syndrome is characterised by microcephaly and growth delay, features also displayed by several related disorders including Majewski (microcephalic) osteodysplastic primordial dwarfism (MOPD) type II and Meier-Gorlin Syndrome (MGS). The identification of an ATRIP–deficient patient provides a novel genetic defect for Seckel Syndrome. Coupled with the identification of further ATR–deficient patients, our findings allow a spectrum of clinical features that can be ascribed to the ATR–ATRIP deficient sub-class of Seckel Syndrome. ATR–ATRIP patients are characterised by extremely severe microcephaly and growth delay, microtia (small ears), micrognathia (small and receding chin), and dental crowding. While aberrant bone development was mild in the original ATR–SS patient, some of the patients described here display skeletal abnormalities including, in one patient, small patellae, a feature characteristically observed in Meier-Gorlin Syndrome. Collectively, our analysis exposes an overlapping clinical manifestation between the disorders but allows an expanded spectrum of clinical features for ATR–ATRIP Seckel Syndrome to be defined.
Nature Genetics | 2015
Nadia A. Akawi; Jeremy McRae; Morad Ansari; Meena Balasubramanian; Moira Blyth; Angela F. Brady; Stephen Clayton; Trevor Cole; Charu Deshpande; Tomas Fitzgerald; Nicola Foulds; Richard Francis; George C. Gabriel; Sebastian S. Gerety; Judith A. Goodship; Emma Hobson; Wendy D Jones; Shelagh Joss; Daniel A. King; Nikolai T. Klena; Ajith Kumar; Melissa Lees; Chris Lelliott; Jenny Lord; Dominic McMullan; Mary O'Regan; Deborah Osio; Virginia Piombo; Elena Prigmore; Diana Rajan
Discovery of most autosomal recessive disease-associated genes has involved analysis of large, often consanguineous multiplex families or small cohorts of unrelated individuals with a well-defined clinical condition. Discovery of new dominant causes of rare, genetically heterogeneous developmental disorders has been revolutionized by exome analysis of large cohorts of phenotypically diverse parent-offspring trios. Here we analyzed 4,125 families with diverse, rare and genetically heterogeneous developmental disorders and identified four new autosomal recessive disorders. These four disorders were identified by integrating Mendelian filtering (selecting probands with rare, biallelic and putatively damaging variants in the same gene) with statistical assessments of (i) the likelihood of sampling the observed genotypes from the general population and (ii) the phenotypic similarity of patients with recessive variants in the same candidate gene. This new paradigm promises to catalyze the discovery of novel recessive disorders, especially those with less consistent or nonspecific clinical presentations and those caused predominantly by compound heterozygous genotypes.
Human Mutation | 2010
Martijn Kranendijk; Eduard A. Struys; K. Michael Gibson; Wjera V. Wickenhagen; Jose E. Abdenur; Jochen Buechner; Ernst Christensen; Raquel Dodelson de Kremer; Abdellatif Errami; Paul Gissen; Wanda Gradowska; Emma Hobson; Lily Islam; Stanley H. Korman; Thaddeus W. Kurczynski; Bruno Maranda; Concetta Meli; Cristiano Rizzo; Claude Sansaricq; Friedrich K. Trefz; Rachel Webster; Cornelis Jakobs; Gajja S. Salomons
We performed molecular, enzyme, and metabolic studies in 50 patients with D‐2‐hydroxyglutaric aciduria (D‐2‐HGA) who accumulated D‐2‐hydroxyglutarate (D‐2‐HG) in physiological fluids. Presumed pathogenic mutations were detected in 24 of 50 patients in the D‐2‐hydroxyglutarate dehydrogenase (D2HGDH) gene, which encodes D‐2‐hydroxyglutarate dehydrogenase (D‐2‐HGDH). Enzyme assay of D‐2‐HGDH confirmed that all patients with mutations had impaired enzyme activity, whereas patients with D‐2‐HGA whose enzyme activity was normal did not have mutations. Significantly lower D‐2‐HG concentrations in body fluids were observed in mutation‐positive D‐2‐HGA patients than in mutation‐negative patients. These results imply that multiple genetic loci may be associated with hyperexcretion of D‐2‐HG. Accordingly, we suggest a new classification: D‐2‐HGA Type I associates with D‐2‐HGDH deficiency, whereas idiopathic D‐2‐HGA manifests with normal D‐2‐HGDH activity and higher D‐2‐HG levels in body fluids compared with Type I patients. It remains possible that several classifications for idiopathic D‐2‐HGA patients with diverse genetic loci will be revealed in future studies. Hum Mutat 31:1–5, 2010.
Journal of Biological Chemistry | 2013
Anna Bode; Sian-Elin Wood; Jonathon G.L. Mullins; Angelo Keramidas; Thomas D. Cushion; Rhys Huw Thomas; William O. Pickrell; Cheney Drew; Amira Masri; Elizabeth A. Jones; Grace Vassallo; Alfred Peter Born; Fusun Alehan; Sharon Aharoni; Gerald Bannasch; Marius Bartsch; Bülent Kara; Amanda Krause; Elie G. Karam; Stephanie Matta; Vivek Jain; Hanna Mandel; Michael Freilinger; Gail E. Graham; Emma Hobson; Sue Chatfield; Catherine Vincent-Delorme; Jubran E. Rahme; Zaid Afawi; Samuel F. Berkovic
Background: Hyperekplexia mutations have provided much information about glycine receptor structure and function. Results: We identified and characterized nine new mutations. Dominant mutations resulted in spontaneous activation, whereas recessive mutations precluded surface expression. Conclusion: These data provide insight into glycine receptor activation mechanisms and surface expression determinants. Significance: The results enhance our understanding of hyperekplexia pathology and glycine receptor structure-function. Hyperekplexia is a syndrome of readily provoked startle responses, alongside episodic and generalized hypertonia, that presents within the first month of life. Inhibitory glycine receptors are pentameric ligand-gated ion channels with a definitive and clinically well stratified linkage to hyperekplexia. Most hyperekplexia cases are caused by mutations in the α1 subunit of the human glycine receptor (hGlyR) gene (GLRA1). Here we analyzed 68 new unrelated hyperekplexia probands for GLRA1 mutations and identified 19 mutations, of which 9 were novel. Electrophysiological analysis demonstrated that the dominant mutations p.Q226E, p.V280M, and p.R414H induced spontaneous channel activity, indicating that this is a recurring mechanism in hGlyR pathophysiology. p.Q226E, at the top of TM1, most likely induced tonic activation via an enhanced electrostatic attraction to p.R271 at the top of TM2, suggesting a structural mechanism for channel activation. Receptors incorporating p.P230S (which is heterozygous with p.R65W) desensitized much faster than wild type receptors and represent a new TM1 site capable of modulating desensitization. The recessive mutations p.R72C, p.R218W, p.L291P, p.D388A, and p.E375X precluded cell surface expression unless co-expressed with α1 wild type subunits. The recessive p.E375X mutation resulted in subunit truncation upstream of the TM4 domain. Surprisingly, on the basis of three independent assays, we were able to infer that p.E375X truncated subunits are incorporated into functional hGlyRs together with unmutated α1 or α1 plus β subunits. These aberrant receptors exhibit significantly reduced glycine sensitivity. To our knowledge, this is the first suggestion that subunits lacking TM4 domains might be incorporated into functional pentameric ligand-gated ion channel receptors.
European Journal of Human Genetics | 2015
Dorien Schepers; Alexander J. Doyle; Gretchen Oswald; Elizabeth Sparks; Loretha Myers; Patrick J. Willems; Sahar Mansour; Michael A. Simpson; Helena Frysira; Anneke Maat-Kievit; Rick van Minkelen; Jeanette Hoogeboom; Geert Mortier; Hannah Titheradge; Louise Brueton; Lois J. Starr; Zornitza Stark; Charlotte W. Ockeloen; Charles Marques Lourenço; Ed Blair; Emma Hobson; Jane A. Hurst; Isabelle Maystadt; A Destree; Katta M. Girisha; Michelle S. Miller; Harry C. Dietz; Bart Loeys; Lut Van Laer
Shprintzen–Goldberg syndrome (SGS) is a rare, systemic connective tissue disorder characterized by craniofacial, skeletal, and cardiovascular manifestations that show a significant overlap with the features observed in the Marfan (MFS) and Loeys–Dietz syndrome (LDS). A distinguishing observation in SGS patients is the presence of intellectual disability, although not all patients in this series present this finding. Recently, SGS was shown to be due to mutations in the SKI gene, encoding the oncoprotein SKI, a repressor of TGFβ activity. Here, we report eight recurrent and three novel SKI mutations in eleven SGS patients. All were heterozygous missense mutations located in the R-SMAD binding domain, except for one novel in-frame deletion affecting the DHD domain. Adding our new findings to the existing data clearly reveals a mutational hotspot, with 73% (24 out of 33) of the hitherto described unrelated patients having mutations in a stretch of five SKI residues (from p.(Ser31) to p.(Pro35)). This implicates that the initial molecular testing could be focused on mutation analysis of the first half of exon 1 of SKI. As the majority of the known mutations are located in the R-SMAD binding domain of SKI, our study further emphasizes the importance of TGFβ signaling in the pathogenesis of SGS.
American Journal of Human Genetics | 2016
Margot R.F. Reijnders; Vasilios Zachariadis; Brooke Latour; Lachlan A. Jolly; Grazia M. Mancini; Rolph Pfundt; Ka Man Wu; Conny M. A. van Ravenswaaij-Arts; Hermine E. Veenstra-Knol; Britt Marie Anderlid; Stephen A. Wood; Sau Wai Cheung; Angela Barnicoat; Frank J. Probst; Pilar L. Magoulas; Alice S. Brooks; Helena Malmgren; Arja Harila-Saari; Carlo M. Marcelis; Maaike Vreeburg; Emma Hobson; V. Reid Sutton; Zornitza Stark; Julie Vogt; Nicola S. Cooper; Jiin Ying Lim; Sue Price; Angeline Hwei Meeng Lai; Deepti Domingo; Bruno Reversade
Mutations in more than a hundred genes have been reported to cause X-linked recessive intellectual disability (ID) mainly in males. In contrast, the number of identified X-linked genes in which de novo mutations specifically cause ID in females is limited. Here, we report 17 females with de novo loss-of-function mutations in USP9X, encoding a highly conserved deubiquitinating enzyme. The females in our study have a specific phenotype that includes ID/developmental delay (DD), characteristic facial features, short stature, and distinct congenital malformations comprising choanal atresia, anal abnormalities, post-axial polydactyly, heart defects, hypomastia, cleft palate/bifid uvula, progressive scoliosis, and structural brain abnormalities. Four females from our cohort were identified by targeted genetic testing because their phenotype was suggestive for USP9X mutations. In several females, pigment changes along Blaschko lines and body asymmetry were observed, which is probably related to differential (escape from) X-inactivation between tissues. Expression studies on both mRNA and protein level in affected-female-derived fibroblasts showed significant reduction of USP9X level, confirming the loss-of-function effect of the identified mutations. Given that some features of affected females are also reported in known ciliopathy syndromes, we examined the role of USP9X in the primary cilium and found that endogenous USP9X localizes along the length of the ciliary axoneme, indicating that its loss of function could indeed disrupt cilium-regulated processes. Absence of dysregulated ciliary parameters in affected female-derived fibroblasts, however, points toward spatiotemporal specificity of ciliary USP9X (dys-)function.
Nature Genetics | 2017
John J. Reynolds; Louise S. Bicknell; Paula Carroll; Martin R. Higgs; Ranad Shaheen; Jennie E. Murray; Dimitrios K. Papadopoulos; Andrea Leitch; Olga Murina; Žygimantė Tarnauskaitė; Sarah R. Wessel; Anastasia Zlatanou; Audrey Vernet; Alex von Kriegsheim; Rachel M A Mottram; Clare V. Logan; Hannah Bye; Yun Li; Alexander Brean; Sateesh Maddirevula; Rachel Challis; Kassiani Skouloudaki; Agaadir Almoisheer; Hessa S. Alsaif; Ariella Amar; Natalie J. Prescott; Michael B. Bober; Angela L. Duker; Eissa Faqeih; Mohammed Zain Seidahmed
To ensure efficient genome duplication, cells have evolved numerous factors that promote unperturbed DNA replication and protect, repair and restart damaged forks. Here we identify downstream neighbor of SON (DONSON) as a novel fork protection factor and report biallelic DONSON mutations in 29 individuals with microcephalic dwarfism. We demonstrate that DONSON is a replisome component that stabilizes forks during genome replication. Loss of DONSON leads to severe replication-associated DNA damage arising from nucleolytic cleavage of stalled replication forks. Furthermore, ATM- and Rad3-related (ATR)-dependent signaling in response to replication stress is impaired in DONSON-deficient cells, resulting in decreased checkpoint activity and the potentiation of chromosomal instability. Hypomorphic mutations in DONSON substantially reduce DONSON protein levels and impair fork stability in cells from patients, consistent with defective DNA replication underlying the disease phenotype. In summary, we have identified mutations in DONSON as a common cause of microcephalic dwarfism and established DONSON as a critical replication fork protein required for mammalian DNA replication and genome stability.